Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results

globenewswire.com
BVS The company reported strong Q4 and full-year 2025 results, with revenue growth, improved margins, and increased net income. Management expressed confidence in future growth and shareholder value.

Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2025, and provided its financial guidance for full-year 2026.

"Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened our portfolio, drove above-market growth, improved margins, and strengthened our balance sheet,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “These results reflect continued demand for our market-leading therapies, and disciplined execution across our commercial and operational initiatives. We are entering 2026 from a position of strength and plan to invest to further accelerate our growth while expanding profitability and generating meaningful cash flow. We believe this is a powerful combination that positions Bioventus to deliver increased shareholder value.”

Fourth Quarter 2025 Financial Results

For the fourth quarter, worldwide revenue totaled $157.9 million, advancing 10.0% on an organic* basis driven by double-digit organic* growth across Pain Treatments and Surgical Solutions. Reported revenue increased 2.8% from $153.6 million in the prior-year period due to the impact of the prior-year divestiture of the Advanced Rehabilitation Business.

Net income attributable to Bioventus Inc. was $14.8 million, compared to net loss attributable to Bioventus Inc. of $0.4 million in the prior-year period.

Adjusted EBITDA* of $36.7 million advanced 30% from $28.3 million in the prior-year period as a result of higher organic* revenue growth, increased gross margin and disciplined spending.

GAAP earnings of $0.21 per diluted share of Class A common stock improved from no income per share in the prior-year period. Adjusted Earnings Per Share (Adjusted EPS)* of Class A common stock of $0.24 per diluted share compares to $0.26** per diluted share in the prior-year period as improved operating profit and lower interest expense were more than offset by unfavorable tax expense.

Full-Year 2025 Financial Results

Bioventus’ full-year 2025 worldwide revenue totaled $568.1 million, a decrease of 0.9% compared to the prior-year period due to the divestiture of the Advanced Rehabilitation Business. On an organic* basis, revenue increased 7.5%, driven by above-market growth across all three businesses in the Company's portfolio.

Full-year 2025 net income attributable to Bioventus was $22.7 million, compared to net loss attributable to Bioventus Inc. of $36.1 million in the prior-year period. Adjusted EBITDA* of $116.3 million increased 6.8% from $108.9 million last year due to strong organic* revenue growth and gross margin expansion.

GAAP earnings of $0.33 per diluted share of Class A common stock improved from a loss of $0.56 per diluted share last year. Adjusted earnings per diluted share* was $0.68, reflecting a 21.4% increase compared to $0.56** per diluted share in the prior-year period.

Pain Treatments: Global revenue of $79.7 million accelerated 15.1% primarily due to strong demand for the Company's differentiated portfolio of hyaluronic acid therapies for knee osteoarthritis.

Surgical Solutions: Global revenue of $55.5 million advanced 3.4% driven by higher U.S. demand for Bone Graft Substitutes.

Restorative Therapies: Global revenue of $22.7 million reflects the divestiture of the Advanced Rehabilitation Business at the end of 2024. On an organic* basis, revenue grew 10.3%, driven by improvement in commercial effectiveness and sales force execution with the EXOGEN Bone Stimulation System.

U.S.: Revenue of $139.5 million increased 3.2% and advanced 10.1% on an organic* basis, driven by strong demand across the Company's broad portfolio.

International: Revenue of $18.4 million decreased 0.1%, but increased 9.5% on an organic* basis as a result of significant growth in Pain Treatments. Surgical Solutions revenue was impacted due to the timing of distributor orders.

The following tables represent net sales by business and geographic region for the years ended December 31, 2025 and December 31, 2024:

Pain Treatments: Global revenue of $279.1 million accelerated 6.8% primarily due to strong global demand for the Company's differentiated hyaluronic acid therapies for knee osteoarthritis.

Surgical Solutions: Global revenue of $203.7 million advanced 7.6% as higher U.S. demand for both Bone Graft Substitutes and Ultrasonics, due to their strong clinical and health economic value propositions.

Restorative Therapies: Global revenue of $85.4 million reflects the divestiture of the Advanced Rehabilitation Business at the end of 2024. On an organic* basis, revenue grew 9.3% driven by improvement in commercial effectiveness and sales force execution with the EXOGEN Bone Stimulation System.

U.S.: Revenue of $502.1 million decreased 0.9% and advanced 6.9% on an organic* basis driven by solid demand across the Company's diversified portfolio.

International: Revenue of $66.0 million decreased 0.7%, but increased 11.5% on an organic* basis as a result of growth in Pain Treatments and Surgical Solutions.

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Surgical Solutions and Restorative Therapies. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and X. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

(1) The three months ended December 31, 2025 and December 31, 2024 covered the periods beginning September 28, 2025 and September 29, 2024, respectively.

(1) The three months ended December 31, 2025 and 2024 covered the periods beginning September 28, 2025 and September 29, 2024, respectively.

Reconciliation of Net Income (Loss) to Adjusted EBITDA (unaudited)

*See below under “Use of Non-GAAP Financial Measures” for more details.

**The prior-year period has been recast to conform to the current period presentation of Adjusted EPS*. See below under “Prior Period Recast” for further information.

Investor Inquiries and Media:

Dave Crawford

Bioventus

investor.relations@bioventus.com